You are here: Industry Insights > Market News > M&As this week: Zhejiang Hisoar Pharmaceutical, tella

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

M&As this week: Zhejiang Hisoar Pharmaceutical, tella

pharmaceufical-technologySeptember 30, 2017

Tag: Zhejiang Hisoar Pharmaceutical , tella

Favorites

Chinese pharmaceutical company Zhejiang Hisoar Pharmaceutical plans to divest a 16.1% stake in a biotechnology company.

The sale is planned to be made to limited partnerships and individuals for CNY144m ($21.8m).

Regenerative and cell medicines developer tella has divested a 44.4% stake in a cell processing facilities consolidated subsidiary.

"Regenerative and cell medicines developer tella has divested a 44.4% stake in a cell processing facilities consolidated subsidiary."

tella has received CNY110m ($0.98m) as consideration from the sale.

Both entities involved in the transaction are based in Japan.

Previous:Deals this week: Mithra, Hainan Haiyao, TherapeuticsMD

Next:GSK’s Benlysta receives Japanese MHLW approval for systemic lupus erythematosus

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

M&As this week: Zhejiang Hisoar Pharmaceutical, tella | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

M&As this week: Zhejiang Hisoar Pharmaceutical, tella

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

M&As this week: Zhejiang Hisoar Pharmaceutical, tella

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>